These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 34508017)
1. HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME). Grillini M; Ricci C; Pino V; Pedrini S; Fiorentino M; Corti B Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):14-18. PubMed ID: 34508017 [TBL] [Abstract][Full Text] [Related]
2. Expression of Melan-A in cutaneous granular cell tumours: a diagnostic pitfall. Van Winden VI; Wong DD; Wood BA; Filion P; Harvey NT Pathology; 2024 Feb; 56(1):47-51. PubMed ID: 37989630 [TBL] [Abstract][Full Text] [Related]
3. Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens. Saad M; Cantley R; Hao W; Wang Z; Thomas D; Pantanowitz L; Jin X Diagn Cytopathol; 2024 Jul; 52(7):362-368. PubMed ID: 38558495 [TBL] [Abstract][Full Text] [Related]
4. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors. Alomari AK; Tharp AW; Umphress B; Kowal RP J Cutan Pathol; 2021 Sep; 48(9):1115-1123. PubMed ID: 33660310 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors. Rasic D; Korsgaard N; Marcussen N; Precht Jensen EM Ann Diagn Pathol; 2023 Dec; 67():152211. PubMed ID: 37717457 [TBL] [Abstract][Full Text] [Related]
6. FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study. Zengin HB; Yildiz B; Pukhalskaya T; Smoller BR J Cutan Pathol; 2023 Mar; 50(3):247-258. PubMed ID: 36454046 [TBL] [Abstract][Full Text] [Related]
7. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma. Bahmad HF; Oh KS; Alexis J J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299 [TBL] [Abstract][Full Text] [Related]
8. PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience. Carvajal P; Zoroquiain P Pathol Res Pract; 2023 Oct; 250():154776. PubMed ID: 37696245 [TBL] [Abstract][Full Text] [Related]
9. PRAME expression in melanocytic lesions of the nail. Parra O; Linos K; Li Z; Yan S J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors. Lezcano C; Jungbluth AA; Busam KJ Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605 [TBL] [Abstract][Full Text] [Related]
11. [Application of immunohistochemical staining of PRAME in differential diagnosis between melanoma and melanocytic nevus]. Du J; Yu WJ; Guo RP; Su J Zhonghua Bing Li Xue Za Zhi; 2022 Jul; 51(7):621-626. PubMed ID: 35785832 [No Abstract] [Full Text] [Related]
12. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). Clarkson KS; Sturdgess IC; Molyneux AJ J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130 [TBL] [Abstract][Full Text] [Related]
13. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms. Googe PB; Flanigan KL; Miedema JR Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry for Preferentially Expressed Antigen in Melanoma in the Differential Diagnosis of Melanocytic Lesions of the Nail Apparatus. Krajisnik A; Gharavi NM; Faries MB; Balzer BL; Frishberg DP; Martelli M; Shon W Am J Dermatopathol; 2022 Jul; 44(7):488-492. PubMed ID: 35120028 [TBL] [Abstract][Full Text] [Related]
15. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977 [TBL] [Abstract][Full Text] [Related]
16. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi. Lohman ME; Steen AJ; Grekin RC; North JP J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032 [TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of HMB45 and negative PRAME expression in halo nevi. Ruby KN; Li Z; Yan S J Cutan Pathol; 2021 Apr; 48(4):519-525. PubMed ID: 33184871 [TBL] [Abstract][Full Text] [Related]
18. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730 [TBL] [Abstract][Full Text] [Related]
19. Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation. Fattori A; de la Fouchardière A; Cribier B; Mitcov M Hum Pathol; 2022 Mar; 121():19-28. PubMed ID: 34990622 [TBL] [Abstract][Full Text] [Related]